Introduction
chronic heart failure, cardiovascular death, atherosclerotic, acute coronary syndrome, heart failure, infarct, Atherosclerosis, diabetes
ACUTE MYOCARDIAL INFARCTION, CHRONIC HEART FAILURE, INFLAMMATORY RESPONSE, CHRONIC INFLAMMATORY DISEASE, ACUTE CORONARY SYNDROME, AMI, EVENTS, HEART FAILURE, INFARCT, ATHEROSCLEROSIS, DIABETES
Atherosclerosis (AS) is a chronic inflammatory disease of the arterial wall and, atherosclerotic plaques, when ruptured, are the primary underlying cause of acute myocardial infarction [On the other hand, the SGLT2-I AMI Protect registry showed that chronic application of sodium glucose linked transporter 2 inhibitors (SGLT2-I) significantly lowered inflammatory parameters at the time of admission and 24 h after AMI in patients with diabetes as compared to other oral anti-hyperglycaemic agents as a significant predictor of reduced inflammatory response (OR 0.457, 95% CI 0.275–0.758, p = 0.002) levels. Furthermore, patients on SGLT2-I therapy were found to have less hyperglycaemic events and smaller infarct size at admission compared to SGLT2-I naïve patients [SGLT2-I therapy reduces the risk of cardiovascular death or hospitalization for heart failure in chronic heart failure with reduced ejection fraction (HFrEF), regardless of the presence or absence of diabetes [The EMMY trial showed a significant reduction in NTproBNP levels in patients with acute coronary syndrome for Empagliflozin compared to placebo, independent of diabetes status [This post-hoc analysis of the EMMY trial investigated inflammatory markers, their trajectories following acute myocardial infarction, their relation to functional cardiac parameters and the interplay with SGLT2-I.